Skip to main content
Premium Trial:

Request an Annual Quote

People In The News: Jun 18, 2010

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Mark McGowan has been named interim president and CEO of CombiMatrix, effective July 1. McGowan, who is also chairman of CombiMatrix's board of directors, will replace outgoing President and CEO Amit Kumar, who has led the firm for the past decade.
CombiMatrix said that it recently retained Caldwell Partners to lead the search and recruitment of a permanent president and CEO.

Sequenom said this week that it has elected several members to its board of directors who will serve until 2011, including: Ernst-Günter Afting; Kenneth Buechler; John Fazio; Harry Hixson; Richard Lerner; Ronald Lindsay; and David Pendarvis as directors to hold office until Sequenom’s annual meeting of stockholders in 2011.

Cyntellect has named Saiid Zarrabian, who has been consulting with the company and has been acting CEO since March, to serve as both president and CEO. Zarrabian has replaced Fred Koller, who has taken on the role of company chief technology officer.

Zarrabian formerly was president and chief operating officer of the flavoring developer Senomyx, COO of Pharmacopeia, and president and COO of Molecular Simulations.

Benitec has named Peter French as its new CEO, replacing Sue MacLeman.

French previously served as Benitec's chief scientific officer. He holds a PhD in cell biology from Australia's Commonwealth Scientific and Industrial Research Organization.

Michael Egholm has left his post as CTO and vice president of research and development at 454 Life Sciences, a unit of Roche, to become CTO of Pall, which provides filtration, separation, and purification products.

Todd Arnold has been promoted to vice president of development at 454 and will lead the firm's product development efforts "as we continue to launch innovative, enabling products for the sequencing market," according to a 454 spokesperson. Arnold joined 454 almost four years ago from 3M.

Predictive Biosciences announced this week that Jay Moorin has joined its board of directors.
Moorin is a founding partner at ProQuest Investments, which led a recent Series C funding round through which Predictive raised $25 million. Prior to founding ProQuest, Moorin was CEO of Magainin Pharmaceuticals (now Genaera), and prior to that he was managing director of healthcare banking at Bear Stearns.

Promoted? Changing jobs? GenomeWeb wants to know. E-mail [email protected] to appear in People In The News, a weekly roundup of industry comings and goings.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.